Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RBC Capital Maintains Outperform on PTC, Raises Price Target to $155

RBC Capital analyst Matthew Hedberg maintains PTC (NASDAQ:PTC) with a Outperform and raises the price target from $140 to $155.
byBenzinga Newsdesk
January 30, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

RBC Capital analyst Matthew Hedberg maintains PTC (NASDAQ:PTC) with a Outperform and raises the price target from $140 to $155.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

C4X Discovery Holdings Signed Exclusive Global License Worth up to $402M with AstraZeneca for the Development and Commercialization of NRF2 Activator Program

By Charles Gross
November 28, 5:54 AM
C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to $402 million1, for its NRF2 Activator program. AstraZeneca will develop and commercialize an oral therapy for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD).

AZN